Search API | Vax-Before-Travel

Search API

0 min read

In the Northern Hemisphere, influenza activity was generally low at interepidemic levels in most countries, according to the World Health Organization (WHO) in Influenza Update N° 477.

As of the end of May 2024, the WHO says elevated flu activity continued to be reported in countries in Central America and the Caribbean.

In the United States, the Centers for Disease Control and Prevention (CDC) confirmed on June 7, 2024, that seasonal influenza activity remains low nationally and is forecasted to resume in Fall 2024.

As the Southern Hemisphere winter season accelerates, countries in South America continue to report elevated influenza activity. Influenza A(H1N1)pdm09 and A(H3N2) viruses have been detected.

The WHO forecasts that influenza infections will increase in the coming months.

Both the WHO and CDC recommend international travelers speak with a healthcare provider about flu shot options before departing abroad.

The CDC recently reported that about 158 million flu vaccines were distributed in the U.S. during the 2023-2024 flu season.

Note: The CDC says most known influenza viruses are dissimilar to avian and pandemic influenza viruses; traditional flu shots are not expected to protect people against bird flu or cow flu.

Vaccine Treats:

Influenza

Image:

Image Caption:

US CDC Flu View data June 7, 2024

Live Blog Update Author:

Don Hackett

Location Tags:

Geneva

Vaccine:

Flumist Quadrivalent Influenza Vaccine

0 min read

A Short Communication published by the journal Influenza and Other Respiratory Diseases added to the research-based and real-world evidence the respiratory syncytial virus (RSV) can be prevented in most infants receiving a new monoclonal antibody (mAb).

RSV is the #1 cause of hospitalization of infants in most countries. In France, hospitalizations with RSV represent 28% of all-cause hospitalizations in children under the age of one during the RSV season.

This new study found a single dose of the extended half-life Beyfortus™ (nirsevimab) was found to be 75.9% effective against RSV-related hospitalization in France.

This long-duration mAb was also 80.6% (61.6–90.3) and 80.4% (61.7–89.9) effective in two sensitivity analyses.

These real-world estimates confirmed the efficacy observed in RSV clinical studies, wrote these researchers on June 5, 2024.

Sanofi and AstraZeneca recently announced they are producing Beyfortus before the 2024-2025 RSV season in the U.S.

On November 16, 2023, the CDC announced the release of the U.S. FDA-approved Beyfortus to physicians and hospitals through the Federal VFC Program and commercial channels.

Vaccine Treats:

Respiratory Syncytial Virus (RSV)

Image:

Image Caption:

Pixabay 2024

Live Blog Update Author:

Karen McClorey Hackett

Location Tags:

Austin

Vaccine:

Beyfortus (Nirsevimab) RSV Antibody

0 min read

The New Jersey Department of Health (NJDOH) today announced a Somerset County resident developed measles following international travel.

As of June 5, 2024, no additional cases have been identified. Secondary cases would be expected to occur no later than June 26, 2024.

This is the second confirmed case of measles reported in NJ in 2024, the first of which was identified in Camden County in January.

In 2019, New Jersey reported a significant travel-related measles outbreak.

The NJDOH urges all residents planning to travel, regardless of destination, to ensure they are current on all routine and travel vaccinations, especially MMR vaccinations.

MMR vaccination services are generally available at travel vaccine clinics and pharmacies in the U.S.

As of June 2024, 52 countries are currently experiencing measles outbreaks, according to the U.S. CDC.

Vaccine Treats:

Measles

Image:

Image Caption:

New Jersey beach - Pixabay 2024

Live Blog Update Author:

Don Hackett

Location Tags:

New Jersey

Vaccine:

Priorix Vaccine

Dengusiil Dengue Vaccine

Serum Institute of India (SII) Pvt. Ltd. Dengusiil tetravalent dengue vaccine live attenuated is conducting clinical research in 2024. The TOI reported Dengusiil was formulated to contain DENV 1, DENV 3, and DENV 4 serotypes at not less than 2.5 log10 PFUs and DENV 2 at not less than 3 log10 PFUs per single dose of 0.5 mL. SII received the vaccine strains from the U.S. National Institutes of Health. Results from a study published in August 2023 reported that the vaccine was highly immunogenic. More than 69% of participants had tetravalent seroconversion, and more than 15 had trivalent seroconversion. These researchers concluded a single dose of dengue vaccine was safe and well tolerated in adults. The vaccine was highly immunogenic, with trivalent or tetravalent seroconversion and seropositivity in most participants.

SII is conducting phase 2 clinical for Dengusiil in 2024. A study published in August 2023 reported that the vaccine was highly immunogenic.

Serum Institute of India is the world's largest vaccine manufacturer in terms of the number of doses produced and sold globally. SII performs high-quality pre-clinical and clinical research in compliance with GLP and GCP guidelines on all its products before they are marketed worldwide. After licensure, diligent pharmacovigilance is maintained as per international norms.

Dengusill Vaccine Availability

SII says Dengusiil intends to be commercialized in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka.

Dengusill Vaccine Indication

Dengue fever virus is transmitted to humans by infected mosquitoes. In 2024, outbreaks were reported in over 100 countries. Dengue is endemic in India, with an overall seroprevalence of 48·7 % (95 % CI 43·5–54·0).

Dengusill Vaccine Side Effects

The phase 1 clinical trial concluded that Dengusill was safe and well tolerated, and no causally related serious adverse event was reported in the study.

Dengusill Vaccine News

November 27, 2023 - HT reported SII would start Phase I & II dengue vaccine trials in India.

Dengusiil Dengue Vaccine Clinical Trials

The Phase I, double-blind, randomized, placebo-controlled trial on 60 healthy individuals aged 18 to 45 years in Australia to assess the safety and immunogenicity of the Dengusiil tetravalent live-attenuated dengue vaccine. The study was conducted from December 2019 - June 2021. Results: 60 participants were randomized to receive dengue vaccine (n = 40) or placebo (n = 20). Twenty-three participants (59 %) showed DENV vaccine viremia post-vaccination for any of the four serotypes, with the majority on days nine and 11. At baseline, all participants were naïve by dengue PRNT50 for all four serotypes in both the study groups except for four in the dengue vaccine group and two in the placebo group. On day 57, the GMTs of neutralizing antibodies ranged from 66.76 (95 % CI 36.63, 121.69) to 293.84 (95 % CI 192.25, 449.11) for all four serotypes in the dengue vaccine group. On day 181, though the titers declined, they still remained much higher than the baseline. The titers in the placebo group did not change after vaccination. Seroconversion through day 85 ranged from 79.5 % for DENV 1 to 100 % for DENV2, while in the placebo group, no participant showed seroconversion through day 85. Similar trends were noted when PRNT was done using wild DENV serotypes in both vaccine and placebo groups.

0 min read

Manufacturer:

Serum Institute of India (SII) Pvt. Ltd

Reviewer:

Robert Carlson, MD

Vaccine:

Dengusiil Dengue Vaccine

VIS:

PDF

Availability:

N/A

Drug Class:

Vaccine, live tetravalent

Clinical Trial Phase I:

A Phase 1 Safety Study of Dengusiil in Healthy Adults

Condition:

Dengue

Last Reviewed:

Thursday, December 5, 2024 - 08:50

Brand:

Dengusill

Status:

Candidate

Manufacturer Country ID:

FDA First In Class:

Yes

UNII:

DB14764

0 min read

According to data published by the U.S. Centers for Disease Control and Prevention (CDC), a UCLA-led multi-site study that included 45% women and 20% children, no mpox cases were reported,

During June–December 2023, among 196 patients in the study, only three mpox cases were identified (1.5%). All cases were among men who reported having sex with multiple men in the month prior and not being vaccinated against mpox.

The CDC's MMWR revealed on June 6, 2024, that clinicians should remain vigilant for mpox virus infections and educate patients about the importance of risk reduction and JYNNEOS® vaccination.

Bavarian Nordic produces the third generation JYNNEOS® (MVA-BN®, IMVAMUNE®), a two-dose vaccine based on a live, attenuated vaccinia virus, Modified Vaccinia Ankara.

A meta-analysis of 16 studies published on April 26, 2024, revealed that the JYNNEOS vaccine effectiveness (VE) for one pre-exposure prophylactic vaccination ranged from 35% to 86%, and VE ranged from 66% to 90% for two doses.

In 2024, JYNNEOS became commercially available in the U.S. Currently, the CDC does not recommend routine immunization against mpox for the general public and has not endorsed JYNNEOS booster doses (3rd).

Vaccine Treats:

mpox

Image:

Image Caption:

by Sohag Hawlader

Live Blog Update Author:

Karen McClorey Hackett

Location Tags:

Atlanta

Vaccine:

JYNNEOS Smallpox Mpox Vaccine

Chlamydia, Gonorrhea, Syphilis Prevention Now Includes Re-Purposed Products

Doxycycline and MenB vaccination prevent bacterial sexually transmitted infections

June 6, 2024

Fact checked by Robert Carlson, MD

0 min read

Liberia is one African nation leading a crucial fight against polio. Unfortunately, Liberia recently reported a resurgence of variant polio type 2 in wastewater.

Liberia reported two variant polio type 2 detections from environmental sampling in 2023 and six so far in 2024.

Although historic polio vaccine coverage rates have shown promising progress, the battle against polio requires unwavering commitment and action, wrote the Global Polio Eradication Initiative on June 4, 2024.

Despite the challenges, the number of variant poliovirus cases in Liberia has significantly declined, with no children paralyzed by polio since 2021.

To stop the spread of the virus quickly, Liberia has launched nationwide immunization campaigns using the novel oral polio vaccine (nOPV2).

The second round of nOPV2 vaccinations is set to begin on June 7, 2024.

Primarily deployed in Africa during the last two years, the nOPV2 vaccine has been offered over 1 billion times.

Mr. Adolphus Clark, Expanded Programme on Immunization Manager in Liberia, expressed his optimism in a media release about the pending vaccination campaign, stating, “Our collective efforts have brought us closer than ever to a polio-free Liberia.... we are renewing our commitment to ensure that every child is protected from this preventable disease.”

Liberia has also introduced seven vaccines into its routine immunization schedule: Pneumococcal Conjugate Vaccine, Rotavirus, Inactive Polio Virus, Haemophilus influenzae Tue B, Typhoid, and measles-containing vaccine.

To alert international visitors, the U.S. CDC has included Liberia in its recent polio and measles Travel Health Advisories. The CDC suggests travelers speak with a travel vaccine expert about immunization options one month before visiting Liberia.

Vaccine Treats:

Polio

Image:

Image Caption:

US State Dept 2024

Live Blog Update Author:

Don Hackett

Location Tags:

Liberia

Vaccine:

nOPV2 Polio Vaccine

Vaccinations Can Reduce New York City's Chickenpox Outbreak

New York City pharmacies offer Varicella vaccines

June 6, 2024

Fact checked by Robert Carlson, MD

0 min read

Auro Vaccines LLC's Nipah Virus vaccine candidate HeV attachment G glycoprotein (HeV-sG-V) was recently found to induce antibodies within one month of vaccination, and the persistence afforded by two dosages suggests the vaccine candidate has the potential for reactive Nipal outbreak control and preventative use.

On May 30, 2024, results from a Phase 1 study funded by the Coalition for Epidemic Preparedness Innovations and published by The Lancet preprint evaluated a recombinant subunit vaccine consisting of a soluble version of HeV-sG-V for safety, tolerability, and immunogenicity. The highest response rates were among vaccinees receiving two administrations of the 100 mcg vaccine candidate 28 days apart.

As of June 6, 2024, several Nipah Virus vaccine candidates were conducting clinical research, but no approved Nipah vaccines were available.

The World Health Organization says that Nipah was first discovered in Malaysia in the 1990s. This virus causes yearly outbreaks throughout South and Southeast Asia, with associated mortality rates of 40 to 75 %. Nipah infection is a zoonotic illness transmitted to people from animals such as bats.

The virus can also be transmitted through contaminated food or from person to person.

The WHO published a Technical Brief in early 2024 as an interim document to guide countries in planning for a Nipah virus event.

No cases of Nipah have been diagnosed in the U.S.

Vaccine Treats:

Nipah virus

Image:

Image Caption:

Nipah virus case map 2024

Live Blog Update Author:

Karen McClorey Hackett

Location Tags:

Austin

0 min read

The U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted today to recommend that COVID-19 vaccines be updated to a monovalent JN.1-lineage composition for 2024-2025 and expressed a preference for the JN.1 strain.

As of June 5, 2024, Novavax Inc. stated in a press release that, pending authorization, it expects to be ready for the commercial delivery of a protein-based JN.1 COVID-19 vaccine in the U.S. in September 2024.

Novavax’s JN.1 COVID-19 vaccine has demonstrated broad cross-neutralizing antibodies for various JN.1 descendant viruses, including KP.2 and KP.3.

'We believe updating to the JN.1 lineage or JN.1, as recommended by the World Health Organization and the European Medicines Agency and as unanimously recommended by VRBPAC today, will provide the protection needed this fall against COVID-19,' wrote the company.

'Our most recent nonclinical data have demonstrated that our JN.1 vaccine candidate induces broad neutralization responses to JN.1 lineage viruses including those with the F456L mutation (e.g., JN.1.16), the R346T mutation (e.g., JN.1.13.1), to “FLiRT” variants that contain both mutations such as KP.2, currently the most common circulating variant in the U.S., and to “FLuQE” variants that are increasing in circulation (e.g., KP.3).'

'Our JN.1 vaccine candidate also produces conserved polyfunctional, Th1-biased CD4+ T cell responses to a range of JN.1 lineage variants, including those containing the F456L, R346T, and FLiRT mutations (e.g., KP.2).'

'These responses indicate that our vaccine technology induces broadly neutralizing responses against multiple variant strains, including circulating forward drift variants.'

Based on data presented by vaccine manufacturers today, the VRBPAC acknowledged the advantages of a JN.1 vaccine in providing broad protection against circulating and future strains and the need to minimize confusion in making public health recommendations.

As of June 2024, Novavax's vaccine is the only protein-based, non-mRNA vaccine available in the U.S. Novavax vaccines have been offered by most pharmacies in the U.S.

Vaccine Treats:

COVID-19

Image:

Image Caption:

by Hosny Salah

Location Tags:

Gaithersburg

Vaccine:

Novavax COVID-19 Vaccine